Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical HSC and NK Cell Transplant for Relapsed Hematologic Malignancies
NCT01621477Phase 2Terminated
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2012
- Primary completion
- Dec 2015
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Natural Killer Cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and 5 more, sponsored by St. Jude Children's Research Hospital. Primary endpoint: One-year Survival at 1 year. Started Aug 2012; status: terminated.
02
Drugs
Natural Killer Cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)juvenile myelomonocytic leukemia (JMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01621477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621477.